Nevertheless, the optimum HER2/CEP17 ratio cut-off for tumor response in BC patients treated with trastuzumab both in the (neo)-adjuvant and metastatic setting is still widely debated [15–19]. The gene discussed is ERBB2; the disease is breast cancer.